Cargando…

Up-Regulation of Urotensin II and Its Receptor Contributes to Human Hepatocellular Carcinoma Growth via Activation of the PKC, ERK1/2, and p38 MAPK Signaling Pathways

Urotensin II (UII) and its receptor (UTR) have mitogenic effects on tumor growth. Our previous study demonstrated that the UII/UTR system is up-regulated in dithyinitrosamine-induced precancerous rat liver lesions. However, its role in human hepatocellular carcinoma remains unknown. In this study, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xiao-Tong, Wang, Peng-Yan, Shi, Zheng-Ming, Dong, Kun, Feng, Ping, Wang, Hong-Xia, Wang, Xue-Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271171/ https://www.ncbi.nlm.nih.gov/pubmed/25514221 http://dx.doi.org/10.3390/molecules191220768

Ejemplares similares

Urotensin-II-Mediated Reactive Oxygen Species Generation via NADPH Oxidase Pathway Contributes to Hepatic Oval Cell Proliferation
por: Yu, XiaoTong, et al.
Publicado: (2015)

Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma
por: Liu, Dian-Gang, et al.
Publicado: (2016)

Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients
por: Wei, Hongtao, et al.
Publicado: (2017)

Quinpirole Increases Melatonin-Augmented Pentobarbital Sleep via Cortical ERK, p38 MAPK, and PKC in Mice
por: Hong, Sa-Ik, et al.
Publicado: (2016)

Urotensin II in cardiovascular regulation
por: Russell, Fraser D
Publicado: (2008)

Leptin Inhibits Glucose Intestinal Absorption via PKC, p38MAPK, PI3K and MEK/ERK
por: El-Zein, Ola, et al.
Publicado: (2013)

Central and Peripheral Effects of Urotensin II and Urotensin II-Related Peptides on Cardiac Baroreflex Sensitivity in Trout
por: Lancien, Frédéric, et al.
Publicado: (2017)

MBD2 Mediates Septic AKI through Activation of PKCη/p38MAPK and the ERK1/2 Axis
por: Xie, Yuxin, et al.
Publicado: (2020)

Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells
por: Park, Sung Lyea, et al.
Publicado: (2013)

Divergent cardio-ventilatory and locomotor effects of centrally and peripherally administered urotensin II and urotensin II-related peptides in trout
por: Vanegas, Gilmer, et al.
Publicado: (2015)

Urotensin II Promotes Atherosclerosis in Cholesterol-Fed Rabbits
por: Li, Yafeng, et al.
Publicado: (2014)

Urotensin II Inhibits Skeletal Muscle Glucose Transport Signaling Pathways via the NADPH Oxidase Pathway
por: Wang, Hong-Xia, et al.
Publicado: (2013)

Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011)

Urotensin-II: More Than a Mediator for Kidney
por: Balat, Ayşe, et al.
Publicado: (2012)

Blockade of Urotensin II Receptor Prevents Vascular Dysfunction
por: Kim, Young-Ae, et al.
Publicado: (2016)

Role of Urotensin-II in Saphenous Vein Graft Disease
por: Tüysüz, Mehmet Erin, et al.
Publicado: (2020)

Urotensin II levels in patients with inflammatory bowel disease
por: Alicic, Damir, et al.
Publicado: (2021)

OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway
por: Li, Hua, et al.
Publicado: (2016)

A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway
por: Kim, Tae-Ho, et al.
Publicado: (2017)

ERK1/2 and p38 MAPKs Are Complementarily Involved in Estradiol 17ß-d-Glucuronide-Induced Cholestasis: Crosstalk with cPKC and PI3K
por: Boaglio, Andrea C., et al.
Publicado: (2012)

Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
por: Merlino, Francesco, et al.
Publicado: (2013)

A closer look at the role of urotensin II in the metabolic syndrome
por: Barrette, Pierre-Olivier, et al.
Publicado: (2012)

Urotensin II in Invertebrates: From Structure to Function in Aplysia californica
por: Romanova, Elena V., et al.
Publicado: (2012)

Irisin levels are associated with urotensin II levels in diabetic patients
por: He, Wan-Yu, et al.
Publicado: (2015)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population
por: Simunovic, Marko, et al.
Publicado: (2022)

Urotensin II level is elevated in inflammatory bowel disease patients
por: Zhang, Yan, et al.
Publicado: (2022)

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction
por: Ogawa, Akiko, et al.
Publicado: (2023)

MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
por: Moon, Hyuk, et al.
Publicado: (2021)

Effect of Repeated Electroacupuncture Intervention on Hippocampal ERK and p38MAPK Signaling in Neuropathic Pain Rats
por: Wang, Jun-ying, et al.
Publicado: (2015)

Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits
por: Yu, Qingqing, et al.
Publicado: (2023)

P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17
por: Tan, Qi, et al.
Publicado: (2017)

Fucoidan Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma via the p38 MAPK/ERK and PI3K/Akt Signal Pathways
por: Duan, Yifei, et al.
Publicado: (2020)

PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior
por: Fu, Yu, et al.
Publicado: (2008)

Hsp90 modulates human sperm capacitation via the Erk1/2 and p38 MAPK signaling pathways
por: Sun, Peibei, et al.
Publicado: (2021)

The Urotensin System Is Up-Regulated in the Pre-Hypertensive Spontaneously Hypertensive Rat
por: Forty, Ellen J., et al.
Publicado: (2013)

An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts
por: LIU, WENYUAN, et al.
Publicado: (2015)

Aluminum Nanoparticles Induce ERK and p38MAPK Activation in Rat Brain
por: Kwon, Jung-Taek, et al.
Publicado: (2013)

Urotensin II levels in patients with chronic kidney disease and kidney transplants
por: Hursitoglu, Mehmet, et al.
Publicado: (2012)

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
por: ZHAO, JUAN, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g3bltn5vi8t5u4aiq8fjmlgq40